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ORIGINAL RESEARCH

The effect of vortioxetine on overall patient functioning in
patients with major depressive disorder
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Background: The objectives of this meta-analysis of data from randomized, placebo-
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controlled studies were to assess the effect of vortioxetine on overall functioning (pri-
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mary) and functional remission (secondary) using the Sheehan Disability Scale (SDS) in
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Methods: Data from nine short-term (6/8 weeks) pivotal studies that included patient
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adults with major depressive disorder (MDD).
functioning assessments were included in this random-effects meta-analysis, which
used aggregated study-level data for all therapeutic vortioxetine doses and a mixed-
effect model for repeated measures using the full analysis set.
Results: A total of 4,216 patients received ≥1 dose of study treatment (1,522 placebo,
2,694 vortioxetine 5–20 mg/day). At study end, the meta-analysis showed improvement for vortioxetine versus placebo (n = 911) in SDS total score (vortioxetine 5 mg,
n = 564, change from baseline versus placebo [Δ] −0.24, p = NS; 10 mg, n = 445, Δ
−1.68, p ≤ .001; 15 mg, n = 204, Δ −0.91, p = NS; 20 mg, n = 340, Δ −1.94, p ≤ .01).
Functional remission (SDS total score ≤6) was observed with vortioxetine 10 mg
(n = 170/573; odds ratio [OR] relative to placebo 1.7, p < .001) and 20 mg (n = 144/447;
OR 1.6, p < .05), but not 5 mg (n = 207/757; OR 1.1, p = NS) or 15 mg (n = 92/295; OR
1.3, p = NS).
Conclusion: Vortioxetine 5–20 mg for 6/8 weeks improved overall patient functioning in patients with MDD. Relative to placebo, vortioxetine 10 and 20 mg demonstrated significant improvement in SDS total score and functional remission.
KEYWORDS

functional impairment, major depressive disorder, quality of life, Sheehan Disability Scale,
vortioxetine

1 | INTRODUCTION

social functioning (Greer, Kurian, & Trivedi, 2010; Kessler et al., 2003;

Patients with major depressive disorder (MDD) experience func-

and economic burden, which can be attributed in part to functional

tional impairment that can negatively affect many aspects of daily

impairment. In 2010, MDD was ranked as the 11th leading cause of

life, including school, work, interpersonal relationships, and overall

disability-adjusted life years worldwide (Ferrari et al., 2013), with an

Moussavi et al., 2007). MDD is associated with significant disability
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associated cost estimated at $210.5 billion in the United States alone,

is becoming increasingly common. Among the myriad of quality of

with approximately half of the cost attributable to disability in the

life, social functioning, and occupational functioning scales avail-

workplace (Greenberg et al., 2015). Restoration of patient functioning

able (Lam et al., 2011), the Sheehan Disability Scale (SDS; Sheehan,

is a desirable goal of MDD treatment (Lam, Filteau, & Milev, 2011);

Harnett-Sheehan, & Raj, 1996) has emerged as a useful tool for this

however, the impact of antidepressant therapy on this outcome re-

purpose. The SDS is a patient-rated measure of functional disability

mains poorly understood. Although improvement in depressive symp-

that assesses the individual’s impairment with regard to their work

toms would be expected to result in improved patient functioning,

and/or school activities, social life and leisure activities, and func-

published evidence suggests that this relationship is variable and com-

tioning in family life and home responsibilities (Sheehan & Sheehan,

plex (Guico-Pabia, Fayyad, & Soares, 2012; Judd et al., 2008; McKnight

2008; Sheehan et al., 1996). The SDS is validated for use in patients

& Kashdan, 2009; Romera et al., 2010; Sheehan et al., 2011; Trivedi

with MDD and is sensitive to the effects of antidepressant treatment

et al., 2009; Zimmerman et al., 2006, 2008, 2012). Notably, functional

(Sheehan & Sheehan, 2008).

impairment may persist beyond the resolution of depressive symp-

The multimodal antidepressant vortioxetine is approved for the

toms in many patients (Judd et al., 2008; McKnight & Kashdan, 2009;

treatment of adults with MDD in the United States and for the treat-

Romera et al., 2010; Sheehan et al., 2011).

ment of major depressive episodes in adults in the European Union.

In clinical studies, the assessment of the beneficial effects of an-

It inhibits the serotonin (5-HT) transporter, is an antagonist at 5-HT3,

tidepressant therapy on functional impairment in patients with MDD

5-HT7, and 5-HT1D receptors, is a partial agonist at 5-HT1B receptors,

T A B L E 1 Summary characteristics of the nine short-term, placebo-controlled studies of vortioxetine in patients with MDD included in the
meta-analysis (APTS)
NCT identifier

Treatment period

Dose mg/day (n)

Key inclusion criteria for MDD

Reference

NCT00635219

8 weeks

VOR 2.5 (155)
VOR 5 (157)
VOR 10 (151)
DUL 60 (155)
PBO (148)

MADRS ≥26
MDE ≥3 months

Baldwin et al. (2012)

NCT00735709

8 weeks

VOR 1 (140)
VOR 5 (140)
VOR 10 (139)
PBO (140)

MADRS ≥26
MDE ≥3 months

Henigsberg et al. (2012)

NCT01140906

8 weeks

VOR 15 (151)
VOR 20 (151)
DUL 60 (147)
PBO (158)

MADRS ≥26
CGI-S ≥4
MDE >3 months recurrent

Boulenger et al. (2014)

NCT01153009

8 weeks

VOR 15 (147)
VOR 20 (154)
DUL 60 (150)
PBO (159)

MADRS ≥26
CGI-S ≥4
MDE ≥3 months recurrent

Mahableshwarkar, Jacobsen,
Chen, et al. (2015)

NCT01163266

8 weeks

VOR 10 (155)
VOR 20 (150)
PBO (157)

MADRS ≥26
CGI-S ≥4
MDE ≥3 months recurrent

Jacobsen et al. (2015)

NCT01255787

8 weeks

VOR 5 (144)
VOR 10 (148)
VOR 20 (150)
PBO (152)

MADRS ≥26
CGI-S ≥4
MDE ≥3 months

Takeda (2013)

NCT00672958

6 weeks

VOR 5 (299)
PBO (298)

MADRS ≥30
MDE ≥3 months

Jain et al. (2013)

NCT00672620

8 weeks

VOR 2.5 (149)
VOR 5 (153)
DUL 60 (150)
PBO (151)

MADRS ≥22
MDE ≥3 months

Mahableshwarkar et al. (2013)

NCT01179516

8 weeks

VOR 10 (154)
VOR 15 (151)
PBO (160)

MADRS ≥26
CGI-S ≥4
MDE >3 months recurrent

Mahableshwarkar, Jacobsen,
Serenko, et al. (2015)

APTS, all patients treated set (n represents all randomized participants who took at least one dose of study medication); CGI-S, Clinical Global Impression–
Severity of Illness; DUL, duloxetine; MADRS, Montgomery-Åsberg Depression Rating Scale; MDD, major depressive disorder; MDE, major depressive episode; PBO, placebo; VEN, venlafaxine; VOR, vortioxetine.
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and is an agonist at 5-HT1A receptors (Bang-Andersen et al., 2011; Mork
et al., 2012; Westrich et al., 2012). In preclinical studies, vortioxetine

T A B L E 2 Summary demographics and baseline characteristics for
patients included in the meta-analysis (APTS)

has demonstrated effects on serotonergic, noradrenergic, dopaminergic, cholinergic, norepinephrinergic, acetylcholinergic, histaminergic, gabanergic, and glutamatergic neurotransmission (Bang-Andersen et al.,
2011; Mork et al., 2012; Sanchez, Asin, & Artigas, 2015). The efficacy
and safety of vortioxetine in patients with MDD has been demonstrated in a series of short- and long-term studies (Alvarez et al., 2012;
Boulenger, Loft, & Olsen, 2014; Henigsberg et al., 2012; Jacobsen et al.,
2015; Katona, Hansen, & Olsen, 2012; Mahableshwarkar, Jacobsen,
Chen, et al., 2015; McIntyre, Lophaven, & Olsen, 2014; Montgomery,
Nielsen, et al., 2014). The effects of vortioxetine on general functioning were assessed (with the SDS) as secondary measures in a subset of
short-term clinical trials (Baldwin, Loft, & Dragheim, 2012; Boulenger
et al., 2014; Henigsberg et al., 2012; Jacobsen et al., 2015; Jain et al.,

Age (years), mean (SD)

Placebo
N = 1,522

Vortioxetine
N = 2,694

43.92 (12.58)

44.43 (12.76)

544 (35.7)

897 (33.3)

Sex, n (%)
Male
Female
Number of previous MDEs,
mean (SD)

978 (64.3)

1,797 (66.7)

2.46 (2.32)

2.45 (2.54)

32.05 (4.08)

32.22 (4.11)

MADRS total score
Mean (SD)
<30, n (%)

424 (27.9)

737 (27.4)

≥30, n (%)

1,098 (72.1)

1,957 (72.6)

19.45 (6.27)

19.73 (6.28)

4.69 (0.67)

4.69 (0.65)

2013; Mahableshwarkar, Jacobsen, & Chen, 2013; Mahableshwarkar,

HAM-A total score, mean (SD)

Jacobsen, Chen, et al., 2015; Mahableshwarkar, Jacobsen, Serenko,

CGI-S score, mean (SD)

et al., 2015; Takeda, 2013). The purpose of this post hoc meta-analysis

SDS total score

n = 1,181

n = 2,009

was to analyze the SDS results from these studies to determine the

Mean (SD)

19.29 (6.04)

19.44 (5.97)

effect of vortioxetine on overall patient functioning as well as the pro-

SDS work/school item
score

n = 1,181

n = 2,010

portion of patients who achieved functional remission versus placebo.

Mean (SD)

2 | MATERIALS AND METHODS

SDS social item score

2.1 | Datasets

SDS family item score

Mean (SD)

The clinical development program for vortioxetine in MDD was conducted in multiple countries. The studies were designed and carried
out in accordance with the principles of the World Medical Association
Declaration of Helsinki, the principles of International Conference
on Harmonisation Harmonised Tripartite Guideline for Good Clinical

3 of 13

Mean (SD)

6.05 (2.54)
n = 1,521
6.80 (2.21)
n = 1,521
6.62 (2.20)

6.26 (2.41)
n = 2,689
6.74 (2.20)
n = 2,690
6.57 (2.20)

APTS, all patients treated set (n represents all randomized participants who
took at least one dose of study medication); CGI-S, Clinical Global
Impressions—Severity of Illness; HAM-A, Hamilton Anxiety Rating Scale;
MADRS, Montgomery-Åsberg Depression Rating Scale; MDE, major depressive episode; SD, standard deviation; SDS, Sheehan Disability Scale.

Practice, and all applicable local or regional regulatory requirements.
The study sponsors (Takeda Pharmaceutical and H. Lundbeck A/S)

Psychiatric Association (APA), 2000) criteria for a major depressive ep-

had overall responsibility for the studies, including those where moni-

isode lasting ≥3 months and were ≥18 years old. Additionally, patients

toring was delegated to a contract research organization. The proto-

were required to have Montgomery-Åsberg Depression Rating Scale

cols, statistical analyses, and statistical reporting for all studies were

(MADRS; Montgomery & Asberg, 1979) scores ≥22 (NCT00672620,

developed in accordance with current scientific research approaches

Mahableshwarkar et al., 2013), ≥30 (NCT00672958, Jain et al., 2013)

and relevant guidelines.

or ≥26 (all other trials; Baldwin et al., 2012; Boulenger et al., 2014;

All pivotal vortioxetine studies that assessed the SDS were

Henigsberg et al., 2012; Jacobsen et al., 2015; Mahableshwarkar,

included in this meta-analysis. Thus, data from nine short-term

Jacobsen, Chen, et al., 2015; Mahableshwarkar, Jacobsen, Serenko,

(6/8 weeks)

et al., 2015; Takeda, 2013; Table 1).

multicenter,

double-blind,

randomized,

placebo-

controlled, parallel-group, fixed-dose clinical studies of vortioxetine
conducted in adults (aged 18–75 years) with MDD were analyzed. The
details of the study design and the results of the nine included trials
have been previously published (Baldwin et al., 2012; Boulenger et al.,

2.2 | Scales and assessments
In each of the included studies, functional impairment was assessed

2014; Henigsberg et al., 2012; Jacobsen et al., 2015; Jain et al., 2013;

using the SDS, a patient-rated measure of functional disability that

Mahableshwarkar, Jacobsen, Chen, et al., 2015; Mahableshwarkar,

quantifies impairment with regard to (1) work/school activities, (2)

Jacobsen, Serenko, et al., 2015; Mahableshwarkar et al., 2013; Takeda,

social life and leisure activities, and (3) family relationships/home

2013). Table 1 provides a summary of treatment dosages, number of

responsibilities using a discretized visual analog rating scale rang-

participants in each dosage arm, treatment duration, and key inclusion

ing from 0 (no impairment) to 1–3 (mild disability), 4–6 (moderate

criteria for each of the trials included in this meta-analysis. All patients

disability), 7–9 (marked disability), and 10 (extreme disability). The

enrolled in these studies met the Diagnostic and Statistical Manual of

three item scores were added to produce the total score, which

Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR; American

ranges from 0 to 30 (Sheehan & Sheehan, 2008; Sheehan et al.,

4 of 13
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N

Difference
(± SE)

Standardized
effect size

P-value

ETRANK
P-value

I-squared

5 mg

100

-0.50 (1.00)

-0.07

0.612

0.837

-

10 mg

97

-2.10 (1.00)

-0.30

0.037

0.170

-

5 mg

97

-1.11 (0.99)

-0.16

0.263

0.161

-

10 mg

83

-1.54 (1.03)

-0.23

0.135

0.211

-

NCT01140906

15 mg

65

-3.24 (1.16)

-0.47

0.005

0.221

-

20 mg

80

-3.92 (1.11)

-0.55

<0.001

0.004

-

NCT01153009

15 mg

77

-0.05 (1.11)

-0.01

0.962

0.684

-

20 mg

77

-0.88 (1.10)

-0.13

0.427

0.617

-

10 mg

89

-1.39 (1.04)

-0.20

0.183

0.906

-

Study
NCT00635219

NCT00735709

NCT01163266

VOR
dose

SDS Total Score
difference from placebo (95% CI)

20 mg

77

-2.40 (1.07)

-0.35

0.025

0.234

-

5 mg

98

-0.09 (0.85)

-0.01

0.919

0.830

-

10 mg

102

-2.01 (0.83)

-0.33

0.016

0.275

-

20 mg

106

-0.92 (0.83)

-0.15

0.268

0.691

-

5 mg

179

0.01 (0.78)

0.00

0.986

0.434

-

NCT00672620

5 mg

90

0.21 (0.93)

0.03

0.826

0.089

-

NCT01179516

10 mg

74

-0.92 (1.25)

-0.12

0.464

0.923

-

15 mg

62

0.69 (1.32)

0.09

0.600

0.441

-

5 mg

564

-0.24 (0.40)

-0.04

0.547

-

0

10 mg

445

-1.68 (0.45)

-0.24

<0.001

-

0

15 mg

204

-0.91 (1.21)

-0.13

0.452

-

67

NCT01255787

NCT00672958

Meta-analysis A:
CRF Worst Case
Score*

Meta-analysis B:
Imputed Average
Score

Meta-analysis C:
Assumed Worst
Case Score

20 mg

340

-1.94 (0.71)

-0.29

0.006

-

48

5 mg

746

-0.44 (0.36)

-

0.216

-

3

10 mg

618

-1.43 (0.38)

-

<0.001

-

0

15 mg

345

-0.81 (1.19)

-

0.498

-

80

20 mg

489

-1.91 (0.83)

-

0.022

-

74
0

5 mg

746

-0.41 (0.35)

-

0.238

-

10 mg

618

-1.38 (0.38)

-

<0.001

-

0

15 mg

345

-0.89 (0.90)

-

0.325

-

66

20 mg

489

-1.88 (0.72)

-

0.009

-

66

-10 -8

-6

-4 -2 0
2
4
6
Worse
Better
than placebo
than placebo

8

F I G U R E 1 Meta-analysis of the difference from placebo in Sheehan Disability Scale (SDS) total score change from baseline at week 6/8:
Total population (full analysis set, mixed-effect model for repeated measure). CRF, case report form; VOR, vortioxetine.*Primary meta-analysis
1996). Functional remission was defined as an SDS total score ≤6,

endpoint for SDS total score, as well as for the three individual items.

which was proposed by Sheehan and Sheehan (2008) and further

Analyses were conducted using the mixed-effect model for repeated

supported by collateral analyses in large datasets by Sheehan and

measures (MMRM) on a modified intent-to-treat population, the full

Sheehan (2008), Sheehan et al. (2008) and Sheehan et al. (2011) and

analysis set (FAS; all randomized patients who received ≥1 dose of

which has been used in other studies of MDD to define functional

study medication and had ≥1 valid postbaseline value for the primary

remission (Mancini et al., 2012; Montgomery, Mansuy, et al., 2014;

endpoint). The MMRM model utilized an unstructured covariance ma-

Sambunaris, Bose, et al., 2014; Sambunaris, Gommoll, et al., 2014;

trix and included terms for site, baseline SDS score by visit interac-

Soares et al., 2014).

tion, and treatment by visit interaction. ETRANK was performed as
a sensitivity analysis on all randomized patients (true intent-to-treat

2.3 | Statistical analysis

population). ETRANK utilizes a nonparametric technique to incorporate timing and reasons for withdrawal into the analysis of incomplete

A random-effects, aggregated, study-level meta-analysis was per-

repeated measures data (Entsuah, 1996). To account for heterogene-

formed using data for all therapeutic doses of vortioxetine (5, 10, 15,

ity in the results between studies, the random-effects approach was

and 20 mg/day), with all clinical results reported as the least squares

chosen, conservatively broadening the confidence intervals (CIs) for

mean difference from placebo in the change from baseline to study

the meta-analysis results.

|
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SDS Single Item
Item 1:
Work/school

Item 2:
Social life/leisure
activities

Item 3:
Family life/home
responsibilities

VOR
dose

SDS Single Item Score
difference from placebo (95% CI)

N

Difference
(± SE)

P-value

I-squared

5 mg

564

-0.08 (0.14)

0.568

0

10 mg

446

-0.46 (0.15)

0.003

0

15 mg

204

-0.23 (0.37)

0.540

56

20 mg

340

-0.51 (0.20)

0.011

22

5 mg

746

-0.14 (0.12)

0.247

0

10 mg

618

-0.56 (0.14)

<0.001

0

15 mg

345

-0.22 (0.41)

0.598

79

20 mg

489

-0.75 (0.29)

0.009

73

5 mg

746

-0.17 (0.13)

0.182

0

10 mg

619

-0.46 (0.14)

<0.001

0

15 mg

345

-0.31 (0.43)

0.473

82

20 mg

489

-0.59 (0.31)

0.056

77

-2.0

-1.5

5 of 13

-1.0

-0.5
0.0
0.5
1.0
Better
Worse
than placebo
than placebo

F I G U R E 2 Meta-analysis of the difference from placebo in Sheehan Disability Scale (SDS) single-item scores change from baseline at week
6/8: Total population (full analysis set, mixed-effect model for repeated measure). VOR, vortioxetine
The level of heterogeneity was expressed in terms of I2 (Higgins,

Additional post hoc analyses included the assessment of func-

Thompson, Deeks, & Altman, 2003), which describes the percentage

tional impairment in patients with severe MDD (MADRS total score

of total variation in the treatment effect across studies that is due

≥30 at baseline), patients with significant functional impairment

to heterogeneity rather than to chance. Standardized effect sizes

(SDS total score ≥18 at baseline), both severe MDD and significant

(SES) were calculated as standardized mean differences (similar in

functional impairment (MADRS total score ≥30 and SDS total score

interpretation to Cohen’s d) based on analysis of covariance and

≥18 at baseline), and high levels of anxious symptoms (Hamilton

MMRM results. Functional remission was evaluated using the last

Anxiety Rating Scale [HAM-A; Hamilton, 1959] total score ≥20 at

observation carried forward (LOCF) technique for imputing missing

baseline). An exploratory analysis was conducted to evaluate the

data. Patients with baseline SDS total score ≤6 (placebo: n = 168,

achievement of double remission in patients working at study end-

vortioxetine: n = 308) were excluded from the remission analysis,

point (based on the FAS using observed cases). Double remission

since they were already in remission prior to beginning treatment.

was defined as both symptomatic remission (MADRS total score

Odds ratios (ORs) were calculated using a two-by-two frequency

≤10) and functional remission (SDS total score ≤6) at study end-

table with 95% CIs. The numbers needed to treat (NNTs) were calcu-

point, and only included working patients (as defined by completion

lated as the reciprocals of the risk differences between vortioxetine

of the SDS work item) with baseline SDS total score >6 to avoid

and placebo.

floor effects.

To account for previously identified issues related to the SDS work
score (Arbuckle et al., 2009; Coles et al., 2014; i.e, missing patient
values due to unemployment during the study), sensitivity analyses

3 | RESULTS

were conducted in which scores on this individual item were calculated using three methods: (A) worst case I (“Case Report Form [CRF]

A total of 4,216 patients (mean age 44 years) were randomized and

Worst Case Score”, where work-related information within the CRF is

received at least one dose of placebo (n = 1,522) or vortioxetine

used to impute a missing work score); (B) imputed average non-miss-

5–20 mg/day (n = 2,694) in the nine clinical trials. Most patients

ing score (“Imputed Average Score”, where the average of the two

(72.5%) had severe MDD (MADRS total score ≥30) at baseline.

available items—social and family—is used to impute the missing work

Demographic and baseline characteristics were similar in the placebo

item); and (C) worst case II (“Assumed Worst Case Score”, where a

and vortioxetine treatment groups (Table 2), with women comprising

worst case score of 10 is assumed and imputed for all missing work

approximately two-thirds of the study population (65.8%).

items). Method A did not provide any additional information since no
imputations were made with this rule in the entire database; therefore,
it was identical to the nonimputation method used for the primary

3.1 | SDS total score

meta-analysis. Missing data were imputed at baseline and all subse-

The meta-analysis of the change from baseline versus placebo on the

quent time points.

SDS total score (FAS, MMRM) at study endpoint is summarized in

6 of 13
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F I G U R E 3 Meta-analysis of the difference from placebo in Sheehan Disability Scale (SDS) total score change from baseline at week 6/8:
Patients with baseline Montgomery-Åsberg Depression Rating Scale (MADRS) ≥30 (full analysis set, mixed-effect model for repeated measure).
VOR, vortioxetine
Figure 1. Both vortioxetine 10 mg (n = 445) and 20 mg (n = 340) dem-

versus placebo for all three single items (work/school [n = 446,

onstrated statistically significantly greater improvements in patient

Δ −0.46, p = .003], social life/leisure activities [n = 618, Δ −0.56,

functioning (SDS total score) relative to placebo (Δ −1.68, p < .001 and

p < .001], and family life/home responsibilities [n = 619, Δ −0.46,

Δ −1.94, p = .006, respectively). Neither vortioxetine 5 mg (n = 564, Δ

p < .001]). Vortioxetine 20 mg demonstrated statistically significant

−0.24, p = .547) or 15 mg (n = 204, Δ −0.91, p = .452) separated from

differences from placebo for Item 1 (work/school [n = 340, Δ −0.51,

placebo. The overall SES supported the clinical relevance of the re-

p = .011]) and Item 2 (social life/leisure activities [n = 489, Δ−0.75,

sults of the change from baseline in SDS total score: −0.04 (5 mg),

p = .009]). For Item 3 (family life/home responsibilities [n = 489]), the

−0.24 (10 mg), −0.13 (15 mg), and −0.29 (20 mg). ETRANK analysis of

difference was −0.59 (p = .056). The differences between vortioxetine

the SDS total score after 6/8 weeks of treatment validated the find-

5 and 15 mg and placebo were not statistically significant.

ings of the MMRM analysis. The two alternative methods of imputation and the standard methodology (meta-analysis A) produced similar
estimates of treatment effect and identical conclusions.

3.3 | Subgroup analyses
Results from the post hoc meta-analysis indicated that the beneficial

3.2 | SDS single-item scores
The meta-analysis of the difference from placebo in SDS single-item

effects of vortioxetine on patient functionality extended to patients
with severe depressive symptoms (MADRS total score ≥30) and/or
significant functional disability (SDS total score ≥18) at baseline, as

scores at study endpoint is summarized in Figure 2. Vortioxetine

well as to those patients with significant level of anxiety symptoms

10 mg demonstrated statistically significantly greater improvements

at baseline (HAM-A total score ≥20). Notably, vortioxetine 10 mg
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F I G U R E 4 Meta-analysis of the difference from placebo in Sheehan Disability Scale (SDS) total score change from baseline at week 6/8:
Patients with baseline SDS ≥18 (full analysis set, mixed-effect model for repeated measure). VOR, vortioxetine
demonstrated statistically significant improvement on the SDS total

(n = 490, OR 1.7, p < .001) and 20 mg (n = 388, OR 1.6, p = .021). There

score relative to placebo in all four subgroups (severe MDD symptoms,

was no separation from placebo with vortioxetine 5 mg (n = 643, OR

n = 323, Δ −1.25, p = .029 [Figure 3]; significant functional impair-

1.1, p = .424) or 15 mg (n = 243, OR 1.4, p = .127). There was a slight

ment, n = 312, Δ −1.93, p = .001 [Figure 4]; severe MDD and signifi-

dose–response trend in the analysis of NNT to achieve functional

cant functional impairment, n = 244, Δ −1.44, p = .039 [Figure 5]; and

remission (vortioxetine 5 mg, NNT = 52; 10 mg, NNT = 15; 15 mg,

high level of anxiety symptoms, n = 227, Δ −1.32, p = .050 [Figure 6]).

NNT = 14; and 20 mg, NNT = 14).

A statistically significant difference from placebo was also found with
vortioxetine 20 mg in the subgroup of patients with significant functional impairment at baseline (n = 219, Δ −2.39, p = .048 [Figure 4]).
The differences between vortioxetine 5 or 15 mg and placebo did not
reach statistical significance in any subgroup analysis of the SDS.

3.5 | Double remission
The meta-analysis of double remission (MADRS total score ≤10
and SDS total score ≤6) in patients with baseline SDS total score
>6 demonstrated that, relative to placebo (n = 182, 17.5%), the

3.4 | Functional remission

odds of achieving composite remission were statistically significantly greater with vortioxetine 10 mg (n = 112, 22.9%, OR 1.8,

The meta-analysis of functional remission (SDS total score ≤6) after up

p < .001) and 20 mg (n = 85, 21.6%, OR 1.6, p = .020), with non-

to 8 weeks of treatment in patients with baseline SDS total score >6 is

significant benefits for vortioxetine 5 mg (n = 119, 18.5%, OR 1.0,

summarized in Figure 7. Relative to placebo, the odds of achieving re-

p = .764) and 15 mg (n = 55, 22.7%, OR 1.3, p = .262). The benefits

mission were statistically significantly greater with vortioxetine 10 mg

for vortioxetine that were observed in the meta-analysis on double

8 of 13
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F I G U R E 5 Meta-analysis of the difference from placebo in Sheehan Disability Scale (SDS) total score change from baseline at week 6/8:
Patients with baseline SDS ≥18 and baseline Montgomery-Åsberg Depression Rating Scale (MADRS) ≥30 (full analysis set, mixed-effect model
for repeated measure).  VOR, vortioxetine
remission were supported by the results seen in the individual stud-

fulfill daily activities for an average of 35.2 days in the past year of their

ies (data not shown).

MDD (Kessler et al., 2003). Understanding the relationship between
MDD and functionality is important, especially considering the cost

4 | DISCUSSION

of lost work productivity due to absenteeism and presenteeism. In a
study by Sheehan et al. (2011), patients with MDD experienced symptomatic remission more frequently than functional remission (38% and

Major depressive disorder is associated with significant functional im-

32%, respectively; Sheehan et al., 2011), showing that depressive and

pairment in many areas, including social, occupational, and physical

functional symptoms do not always move in tandem and underscoring

functioning. The effectiveness of MDD treatment in relation to func-

the need for physicians to address both types of symptoms. A recently

tional outcomes is potentially confounded by the bidirectional relation-

published meta-analysis of vortioxetine demonstrated significant im-

ship of depressive symptoms and functional impairment, as well as by

provement in depressive symptoms (as measured by the MADRS),

premorbid functioning, which may not be accounted for when assessing

with 46%–62% of patients responding to treatment across the doses

the reduction in functional impairment (McKnight & Kashdan, 2009).

(5–20 mg) and 28%–39% achieving remission (5–20 mg; Thase et al.,

The National Comorbidity Survey Replication found that 96.9% of pa-

2016). In the current analysis, functional remission (SDS total score ≤6)

tients with MDD for at least 12 months also suffered from functional

at week 6/8 was 25.5%, 30.4%, 30.9%, and 31.2% for vortioxetine 5,

impairment (in at least one area) associated with their depression, with

10, 15, and 20 mg, respectively. Symptomatic remission rates (MADRS

19.1% of patients reporting their impairment as “very severe” (Kessler

total score ≤10) at these doses in the individual studies ranged from

et al., 2003). These respondents also reported being unable to work or

28.8% to 36.0% for vortioxetine 5 mg, 21.4%–36.0% for vortioxetine

FLOREA et al.
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F I G U R E 6 Meta-analysis of the difference from placebo in Sheehan Disability Scale (SDS) total score change from baseline at week 6/8:
Patients with baseline Hamilton Anxiety Rating Scale (HAM-A) ≥20 (full analysis set, mixed-effect model for repeated measure). VOR, vortioxetine
10 mg, 23.9%–34.9% for vortioxetine 15 mg, and 29.3%–38.4% for

et al., 2010) with results that have been variable with respect to clin-

vortioxetine 20 mg, respectively (Baldwin et al., 2012; Boulenger et al.,

ical significance; however, many of these antidepressants showed

2014; Henigsberg et al., 2012; Jacobsen et al., 2015; Jain et al., 2013;

significant differences versus placebo in the change from baseline

Mahableshwarkar, Jacobsen, Chen, et al., 2015; Mahableshwarkar,

versus placebo in the SDS total score when patients were stratified

Jacobsen, Serenko, et al., 2015; Mahableshwarkar et al., 2013).

by baseline depressive symptom severity. A recent pooled analy-

The inclusion of functional outcomes in clinical trials of anti-

sis showed that treatment with duloxetine (n = 1,029) and SSRIs

depressant therapy is increasingly common. The SDS is a validated

(n = 835) resulted in significantly greater improvements in the SDS

measure of functional impairment that has demonstrated sensitivity

total score (∆ −1.9, p < .001; ∆ −1.7, p < .01, respectively) com-

to impairment and the effects of treatment across a wide range of

pared to placebo (n = 329). Further, higher SDS and higher Hamilton

disorders, including MDD (Sheehan & Sheehan, 2008). The SDS has

Depression Rating Scale (17-item) baseline scores predicted a

been used to assess functional improvement in association with im-

lower probability of functional improvement after active treatment

provements in depressive symptoms for duloxetine (Mancini et al.,

(p < .0001; p < .01, respectively; Sheehan et al., 2016). In general,

2012; Oakes et al., 2012; Sheehan et al., 2011; Wise et al., 2008),

treatment with vortioxetine has demonstrated a similar quantitative

desvenlafaxine (Dunlop et al., 2011; Guico-Pabia et al., 2012; Soares

effect in patients with MDD. In a direct comparison to agomelatine

et al., 2009), paroxetine (Wise et al., 2008), bupropion (Hewett et al.,

(25–50 mg) in patients with an inadequate response to SSRI/SNRI

2010; Soczynska et al., 2014), escitalopram (Romera et al., 2012;

monotherapy, vortioxetine (10–20 mg) had significantly greater re-

Soczynska et al., 2014), venlafaxine (Fann et al., 2015; Hewett et al.,

ductions on the SDS total and item scores after 8 and 12 weeks of

2010), levomilnacipran (Asnis et al., 2013; Sambunaris, Bose, et al.,

treatment (Montgomery, Nielsen, et al., 2014). Vortioxetine 10 mg

2014), and agomelatine (Montgomery, Nielsen, et al., 2014; Zajecka

has also demonstrated numerically larger changes from baseline on

10 of 13
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F I G U R E 7 Meta-analysis of remission rates (Sheehan Disability Scale [SDS] ≤6) at week 6/8: Patients with baseline SDS >6 (full analysis set,
last observation carried forward). VOR, vortioxetine. *Overall rate for meta-analysis placebo population

the SDS total and item scores than venlafaxine XR 150 mg/day after

achievement of functional remission (SDS total score ≤6). Additionally,

8 weeks of treatment in adult patients with MDD in Asia (Wang,

vortioxetine 10 mg daily demonstrated clinically significant benefits on

Gislum, Filippov, & Montgomery, 2015).

all aspects of functioning (SDS single-item scores) in the total popula-

This meta-analysis of SDS data from the vortioxetine clinical trial

tion as well as on overall functioning (SDS total score) in patients with

program indicates that vortioxetine 10 and 20 mg daily provided sta-

severe MDD and/or significant functional impairment or high anxiety

tistically significant and clinically relevant improvement in patient func-

symptoms at baseline. These findings are consistent with the results of

tioning in short-term studies, as measured by (1) the change in SDS

the individual studies, where vortioxetine administration was associ-

total score from baseline to study endpoint versus placebo and (2) the

ated with improvements in patient functioning as well as in depressive
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symptoms (Baldwin et al., 2012; Boulenger et al., 2014; Henigsberg
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10 or 20 mg daily was associated with greater improvement in patient

et al., 2012; Jacobsen et al., 2015; Jain et al., 2013; Mahableshwarkar,

functioning and a greater likelihood of achieving functional remission

Jacobsen, Chen, et al., 2015; Mahableshwarkar, Jacobsen, Serenko,

compared to placebo.

et al., 2015; Mahableshwarkar et al., 2013; Takeda, 2013).
Functional improvement with vortioxetine 5–20 mg in the current
analysis tended to be dose-dependent, with the exception of the 15-

AC KNOW L ED G M ENTS

mg dose. No statistically significant improvements in function were

This study was supported by H. Lundbeck A/S as part of a joint clini-

demonstrated for the vortioxetine 5- or 15-mg treatment groups.

cal development program with Takeda Pharmaceutical Company, Ltd.

Further investigation is warranted to explain these findings; however,

Assistance with writing and manuscript preparation was provided by Mary

it is notable that vortioxetine 15 mg was evaluated in only three of

Tom, Pharm.D., and Philip Sjostedt, B.Pharm., of The Medicine Group.

the nine studies included in the present meta-analysis (Boulenger
et al., 2014; Mahableshwarkar, Jacobsen, Chen, et al., 2015;
Mahableshwarkar, Jacobsen, Serenko, et al., 2015), and a statistically
significant difference from placebo in the change in depressive symptoms and functionality was demonstrated in only one of the three individual studies (Boulenger et al., 2014). Heterogeneity between studies
was also greater at the 15-mg dose level (I2 = 67%; p = .47) than at any
other dose level (0%, 0%, and 48% for 5, 10, and 20 mg, respectively).
This analysis employed three alternative methods of imputation
to account for missing work scores due to unemployment during the
study. All three methods produced similar estimates of treatment effect on SDS total score, providing additional insights into how differ-

CO NFL I C T O F I NT ER ES T
Ioana Florea, Henrik Loft, Natalya Danchenko, Benoit Rive, and Melanie
Brignone are employees of H. Lundbeck A/S.  Elizabeth Merikle and
Paula L. Jacobsen are employees of Takeda Pharmaceuticals Company,
Ltd. David V. Sheehan reports receiving grants from the University of
South Florida College of Medicine   during the conduct of the study
and is a copyright holder of the Sheehan Disability Scale used in this
study. [Correction added on 16 February 2017, after first online publication: the Conflict of Interest statement has been inserted.]

ing statistical methodology can be utilized to address the issues raised
regarding missing work scores.
Results of the current analysis suggest that improvement in overall
functioning with vortioxetine is also observed for those patients with
severe MDD and/or significant functional impairment and those with
high anxiety symptoms at baseline. Previous antidepressant studies
conducted in MDD patients with high anxiety symptoms suggest that
these patients are often difficult to treat, exhibiting a slower or less
robust response, with a higher risk of adverse events and suicidal ideation (Andreescu et al., 2007; Fava et al., 2008).
The results of this analysis add to the growing body of evidence
that suggests that, in addition to improving depressive symptoms, vortioxetine provides functional benefits in patients with MDD. Pooling
of data from multiple, smaller—but relatively similarly designed—clinical trials resulted in a large sample size and greater statistic power to
explore these effects. There are, however, limitations to this analysis
that should be considered when interpreting these results. First, this
was an analysis performed on data from studies that were not powered to show statistical differences in SDS between vortioxetine and
placebo. Second, individual studies used different doses and utilized
different primary efficacy endpoints. Last, all data were from short-
term vortioxetine clinical studies. In light of the demonstrated asynchrony between depressive symptoms and patient functioning, the
prudence of assessing function after such a short course of treatment
is debatable.

5 | CONCLUSION
In this meta-analysis of data from nine short-term (6/8-week) clinical
studies conducted in adults with MDD, treatment with vortioxetine
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